- Home
- JYNT vs AARD Comparison
JYNT vs AARD Comparison
Compare JYNT & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYNT
- AARD
- Stock Information
- Founded
- JYNT 2010
- AARD 2017
- Country
- JYNT United States
- AARD United States
- Employees
- JYNT N/A
- AARD N/A
- Industry
- JYNT Multi-Sector Companies
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- JYNT Miscellaneous
- AARD Health Care
- Exchange
- JYNT Nasdaq
- AARD Nasdaq
- Market Cap
- JYNT 170.3M
- AARD 186.3M
- IPO Year
- JYNT 2014
- AARD 2025
- Fundamental
- Price
- JYNT $10.06
- AARD $8.59
- Analyst Decision
- JYNT Strong Buy
- AARD Strong Buy
- Analyst Count
- JYNT 3
- AARD 5
- Target Price
- JYNT $16.33
- AARD $32.60
- AVG Volume (30 Days)
- JYNT 90.7K
- AARD 167.1K
- Earning Date
- JYNT 11-06-2025
- AARD 11-14-2025
- Dividend Yield
- JYNT N/A
- AARD N/A
- EPS Growth
- JYNT N/A
- AARD N/A
- EPS
- JYNT N/A
- AARD N/A
- Revenue
- JYNT $53,449,713.00
- AARD N/A
- Revenue This Year
- JYNT $8.06
- AARD N/A
- Revenue Next Year
- JYNT $11.18
- AARD N/A
- P/E Ratio
- JYNT N/A
- AARD N/A
- Revenue Growth
- JYNT 277.36
- AARD N/A
- 52 Week Low
- JYNT $9.58
- AARD $4.88
- 52 Week High
- JYNT $13.47
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- JYNT 31.98
- AARD N/A
- Support Level
- JYNT $10.47
- AARD N/A
- Resistance Level
- JYNT $10.74
- AARD N/A
- Average True Range (ATR)
- JYNT 0.26
- AARD 0.00
- MACD
- JYNT -0.04
- AARD 0.00
- Stochastic Oscillator
- JYNT 5.26
- AARD 0.00
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.